![](https://scx1.b-cdn.net/csz/news/tmb/2020/vesicarelsap.jpg)
VESIcare LS approved for neurogenic detrusor overactivity
VESIcare LS (solifenacin succinate) oral suspension is now approved to treat neurogenic detrusor overactivity (NDO) in children 2 years and older, the U.S. Food and Drug Administration announced Tuesday.
May 28, 2020
0
0